Efficacy and toxicities of concurrent chemoradiation for elderly patients with esophageal cancer

Takashi Uno, Koichi Isobe, Hiroyuki Kawakami, Naoyuki Ueno, Hiroki Kobayashi, Hideaki Shimada, Hisahiro Mastubara, Shinichi Okazumi, Yoshihiro Nabeya, Touru Shiratori, Takenori Ochiai, Tetsuya Kawata, Hisao Ito

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: To evaluate the efficacy and toxicity of concurrent chemoradiation in patients with esophageal cancer aged 75 and older. Patients and Methods: Twenty-two elderly patients were treated with concurrent chemoradiation. Seventeen received a combination of cisplatin/carboplatin and 5-fluorouracil, 5 received daily 5-fluorouracil. Total doses of radiotherapy ranged from 50 to 65 Gy. Results: Nineteen out of 22 patients completed the planned chemoradiation. Five in 8 patients (63%) with T1-2 lesion and 1 in 14 patients (7%) with T3-4 lesion achieved complete response (p=0.011). Only 2 patients experienced grade 3 toxicities. Grade 2 or worse hematological toxicities were less frequently observed in patients who received local-field radiotherapy (p=0.006). There was no isolated lymph node recurrence. The median survival time was 9 months. Conclusion: This study showed the potential for chemoradiation in elderly patients. A planning target volume of radiotherapy should include only clinically involved lesions in this setting.

Original languageEnglish
Pages (from-to)2483-2486
Number of pages4
JournalAnticancer Research
Volume24
Issue number4
Publication statusPublished - 2004 Jul
Externally publishedYes

    Fingerprint

Keywords

  • Chemotherapy
  • Elderly
  • Esophageal cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Uno, T., Isobe, K., Kawakami, H., Ueno, N., Kobayashi, H., Shimada, H., Mastubara, H., Okazumi, S., Nabeya, Y., Shiratori, T., Ochiai, T., Kawata, T., & Ito, H. (2004). Efficacy and toxicities of concurrent chemoradiation for elderly patients with esophageal cancer. Anticancer Research, 24(4), 2483-2486.